Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

被引:178
作者
Kavanaugh, Arthur [1 ]
Fleischmann, Roy M. [2 ]
Emery, Paul [3 ]
Kupper, Hartmut [4 ]
Redden, Laura [5 ]
Guerette, Benoit [5 ]
Santra, Sourav [5 ]
Smolen, Josef S. [6 ]
机构
[1] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, San Diego, CA USA
[2] Univ Texas SW Med Ctr Dallas, Div Rheumatol, Dallas, TX 75390 USA
[3] Univ Leeds, Sect Musculoskeletal Dis, Leeds, W Yorkshire, England
[4] Abbott Labs, GPRD, Ludwigshafen, Germany
[5] Abbott Labs, GPRD, Abbott Pk, IL 60064 USA
[6] Med Univ Vienna, Div Rheumatol, Vienna, Austria
关键词
AMERICAN-COLLEGE; THERAPY; RECOMMENDATIONS; DEFINITION; RISK;
D O I
10.1136/annrheumdis-2011-201247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the efficacy and safety of adalimumab plus methotrexate (ADA+MTX) compared with methotrexate monotherapy in achieving stable low disease activity (LDA; disease activity score (DAS28(CRP)) <3.2 at weeks 22 and 26) and clinical, radiographic and functional outcomes in methotrexate-naive patients with early rheumatoid arthritis (RA). Methods 1032 patients with active RA were randomly assigned 1: 1 to ADA+MTX or placebo plus methotrexate (PBO+MTX) for 26 weeks. Treatment modifications were to be made in a subsequent study period based on the achievement of DAS28(CRP) <3.2 at weeks 22 and 26. Post-hoc analyses compared patients achieving stable remission using DAS28 and 2010 ACR/EULAR criteria with those achieving LDA but not remission. Results Among patients completing 6 months, 44% (207/466) ADA+MTX versus 24% (112/460) PBO+MTX patients achieved stable LDA at weeks 22 and 26 (p<0.001). Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all). The only factor predicting stable LDA was disease activity at week 12. Patients achieving ACR/EULAR remission, particularly in the PBO+MTX group, had some advantage in radiographic outcomes compared with patients who only achieved LDA (but not remission). The overall frequency of adverse events was comparable between groups. There were more serious infections and deaths in the ADA+MTX group, with a possible age effect. Conclusions Treatment with ADA+MTX was significantly superior to methotrexate alone with respect to clinical, radiographic and functional outcomes in patients with early active RA. Before initiating treatment with adalimumab, individual patient evaluation of the benefit/risk ratio should be carefully considered.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 22 条
[1]   Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients [J].
Aletaha, Daniel ;
Funovits, Julia ;
Keystone, Edward C. ;
Smolen, Josef S. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (10) :3226-3235
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists [J].
Askling, Johan ;
Fored, C. Michael ;
Brandt, Lena ;
Baecklund, Eva ;
Bertilsson, Lennart ;
Feltelius, Nils ;
Coster, Lars ;
Geborek, Pierre ;
Jacobsson, Lennart T. ;
Lindblad, Staffan ;
Lysholm, Jorgen ;
Rantapaa-Dahlqvist, Solbritt ;
Saxne, Tore ;
van Vollenhoven, Ronald F. ;
Klareskog, Lars .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1339-1344
[4]   Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study [J].
Bakker, M. F. ;
Jacobs, J. W. G. ;
Welsing, P. M. J. ;
Vreugdenhil, S. A. ;
van Booma-Frankfort, C. ;
Linn-Rasker, S. P. ;
Ton, E. ;
Lafeber, F. P. J. G. ;
Bijlsma, J. W. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :1099-1103
[5]   Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: A simulation study [J].
Baron, Gabriel ;
Ravaud, Philippe ;
Samson, Adeline ;
Giraudeau, Bruno .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (01) :25-31
[6]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[7]   Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases [J].
Burmester, G. R. ;
Mease, P. ;
Dijkmans, B. A. C. ;
Gordon, K. ;
Lovell, D. ;
Panaccione, R. ;
Perez, J. ;
Pangan, A. L. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (12) :1863-1869
[8]   Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry [J].
Busquets, Noemi ;
Tomero, Eva ;
Angel Descalzo, Miguel ;
Ponce, Andres ;
Ortiz-Santamaria, Vera ;
Suris, Xavier ;
Carmona, Loreto ;
Gomez-Reino, Juan J. .
RHEUMATOLOGY, 2011, 50 (11) :1999-2004
[9]   Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial [J].
Curtis, Jeffrey R. ;
Yang, Shuo ;
Chen, Lang ;
Park, Grace S. ;
Bitman, Bojena ;
Wang, Brian ;
Navarro-Millan, Iris ;
Kavanaugh, Arthur .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) :206-212
[10]  
Curtis JR, 2011, ARTHRITIS RHEUM S10, V63, P426